GlycoMimetics, Inc. (GLYC): Price and Financial Metrics
GlycoMimetics, Inc. (GLYC)
Today's Latest Price: $3.60 USD
Updated Nov 24 4:00pm
Add GLYC to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
GLYC Stock Summary
- For GLYC, its debt to operating expenses ratio is greater than that reported by only 8.06% of US equities we're observing.
- GLYC's price/sales ratio is 17.51; that's higher than the P/S ratio of 90.86% of US stocks.
- GLYC's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 8.89% of US stocks.
- If you're looking for stocks that are quantitatively similar to Glycomimetics Inc, a group of peers worth examining would be CMRX, SGMO, SRRK, DTIL, and NXTC.
- GLYC's SEC filings can be seen here. And to visit Glycomimetics Inc's official web site, go to www.glycomimetics.com.
GLYC Stock Price Chart Interactive Chart >
GLYC Price/Volume Stats
| Current price | $3.60 | 52-week high | $6.29 |
| Prev. close | $3.65 | 52-week low | $1.82 |
| Day low | $3.54 | Volume | 1,167,600 |
| Day high | $3.86 | Avg. volume | 458,393 |
| 50-day MA | $3.35 | Dividend yield | N/A |
| 200-day MA | $3.30 | Market Cap | 172.18M |
GlycoMimetics, Inc. (GLYC) Company Bio
GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company is developing its lead product candidates include rivipansel, a pan-selectin antagonist, which is in Phase III clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease; and GMI-1271, an E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers. The company was founded in 2003 and is based in Rockville, Maryland.
Loading social stream, please wait...